Update on cystic fibrosis-related diabetes

Journal of Cystic Fibrosis

Volumn 12, Issue 4, 2013, Pages 318-331

  Kelly, Andrea ^a   Moran, Antoinette ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cystic fibrosis; Cystic fibrosis related diabetes; Diabetes; Hyperglycemia

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; ISOPHANE INSULIN; PIG INSULIN;

BLOOD GLUCOSE MONITORING; COMORBIDITY; CYSTIC FIBROSIS; CYSTIC FIBROSIS RELATED DIABETES; DIABETES MELLITUS; DISEASE ASSOCIATION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; GRAFT SURVIVAL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; LUNG FUNCTION; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL STATUS; PANCREAS EXOCRINE INSUFFICIENCY; REVIEW;

CYSTIC FIBROSIS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FORECASTING; HUMANS; HYPOGLYCEMIA;

EID: 84878350788     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2013.02.008     Document Type: Review

References (113)

1. Ize-Ludlow D., Sperling M.A. The classification of diabetes mellitus: a conceptual framework. Pediatr Clin North Am 2005, 52:1533-1552.
2. Caumo A., Luzi L. First-phase insulin secretion: does it exist in real life? Considerations on shape and function. Am J Physiol Endocrinol Metab 2004, 287:E371-E385.
3. Nauck M., Stockmann F., Ebert R., Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986, 29:46-52.
4. Beglinger S., Drewe J., Schirra J., Goke B., D'Amato M., Beglinger C. Role of fat hydrolysis in regulating glucagon-like Peptide-1 secretion. J Clin Endocrinol Metab 2010, 95:879-886.
5. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012, 35(Suppl. 1):S64-S71.
6. Collins F.S., Guyer M.S., Charkravarti A. Variations on a theme: cataloging human DNA sequence variation. Science 1997, 278:1580-1581.
7. Schafer S.A., Machicao F., Fritsche A., Haring H.U., Kantartzis K. New type 2 diabetes risk genes provide new insights in insulin secretion mechanisms. Diabetes Res Clin Pract 2011, 93(Suppl. 1):S9-S24.
8. Vilsboll T., Krarup T., Deacon C.F., Madsbad S., Holst J.J. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001, 50:609-613.
9. Kjems L.L., Holst J.J., Volund A., Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003, 52:380-386.
10. Nauck M.A., Heimesaat M.M., Orskov C., Holst J.J., Ebert R., Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993, 91:301-307.
11. Rachman J., Barrow B.A., Levy J.C., Turner R.C. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 1997, 40:205-211.
12. Nauck M.A., Kleine N., Orskov C., Holst J.J., Willms B., Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993, 36:741-744.
13. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009, 32(Suppl. 1):S62-S67.
14. Lanng S., Thorsteinsson B., Roder M.E., Orskov C., Holst J.J., Nerup J., et al. Pancreas and gut hormone responses to oral glucose and intravenous glucagon in cystic fibrosis patients with normal, impaired, and diabetic glucose tolerance. Acta Endocrinol (Copenh) 1993, 128:207-214.
15. Mohan V., Alagappan V., Snehalatha C., Ramachandran A., Thiruvengadam K.V., Viswanathan M. Insulin and C-peptide responses to glucose load in cystic fibrosis. Diabete Metab 1985, 11:376-379.
16. Moran A., Diem P., Klein D.J., Levitt M.D., Robertson R.P. Pancreatic endocrine function in cystic fibrosis. J Pediatr 1991, 118:715-723.
17. Yung B., Noormohamed F.H., Kemp M., Hooper J., Lant A.F., Hodson M.E. Cystic fibrosis-related diabetes: the role of peripheral insulin resistance and beta-cell dysfunction. Diabet Med 2002, 19:221-226.
18. Gottlieb P.A., Yu L., Babu S., Wenzlau J., Bellin M., Frohnert B.I., et al. No relation between cystic fibrosis-related diabetes and type 1 diabetes autoimmunity. Diabetes Care 2012, 35:e57.
19. Iannucci A., Mukai K., Johnson D., Burke B. Endocrine pancreas in cystic fibrosis: an immunohistochemical study. Hum Pathol 1984, 15:278-284.
20. Abdul-Karim F.W., Dahms B.B., Velasco M.E., Rodman H.M. Islets of Langerhans in adolescents and adults with cystic fibrosis. A quantitative study. Arch Pathol Lab Med 1986, 110:602-606.
21. Soejima K., Landing B.H. Pancreatic islets in older patients with cystic fibrosis with and without diabetes mellitus: morphometric and immunocytologic studies. Pediatr Pathol 1986, 6:25-46.
22. Stalvey M.S., Muller C., Schatz D.A., Wasserfall C.H., Campbell-Thompson M.L., Theriaque D.W., et al. Cystic fibrosis transmembrane conductance regulator deficiency exacerbates islet cell dysfunction after beta-cell injury. Diabetes 2006, 55:1939-1945.
23. Solomon M.P., Wilson D.C., Corey M., Kalnins D., Zielenski J., Tsui L.C., et al. Glucose intolerance in children with cystic fibrosis. J Pediatr 2003, 142:128-132.
24. Couce M., O'Brien T.D., Moran A., Roche P.C., Butler P.C. Diabetes mellitus in cystic fibrosis is characterized by islet amyloidosis. J Clin Endocrinol Metab 1996, 81:1267-1272.
25. Lorenzo A., Razzaboni B., Weir G.C., Yankner B.A. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 1994, 368:756-760.
26. Huang C.J., Haataja L., Gurlo T., Butler A.E., Wu X., Soeller W.C., et al. Induction of endoplasmic reticulum stress-induced beta-cell apoptosis and accumulation of polyubiquitinated proteins by human islet amyloid polypeptide. Am J Physiol Endocrinol Metab 2007, 293:E1656-E1662.
27. Huang C.J., Lin C.Y., Haataja L., Gurlo T., Butler A.E., Rizza R.A., et al. High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. Diabetes 2007, 56:2016-2027.
28. Lanng S., Thorsteinsson B., Pociot F., Marshall M.O., Madsen H.O., Schwartz M., et al. Diabetes mellitus in cystic fibrosis: genetic and immunological markers. Acta Paediatr 1993, 82:150-154.
29. Blackman S. A susceptibility gene for type 2 diabetes is a genetic modifier of diabetes complicating cystic fibrosis. Unpublished data, discussed at Pedatric Academic Society Meeting, Baltimore, MD, May 2009. 2009.
30. Ross S.A., Morrison D., McArthur R.G. Hypersecretion of gastric inhibitory polypeptide in nondiabetic children with cystic fibrosis. Pediatrics 1981, 67:252-254.
31. Kuo P., Stevens J.E., Russo A., Maddox A., Wishart J.M., Jones K.L., et al. Gastric emptying, incretin hormone secretion, and postprandial glycemia in cystic fibrosis-effects of pancreatic enzyme supplementation. J Clin Endocrinol Metab 2011, 96:E851-E855.
32. Anzeneder L., Kircher F., Feghelm N., Fischer R., Seissler J. Kinetics of insulin secretion and glucose intolerance in adult patients with cystic fibrosis. Horm Metab Res 2011, 43:355-360.
33. Moran A., Milla C., Ducret R., Nair K.S. Protein metabolism in clinically stable adult cystic fibrosis patients with abnormal glucose tolerance. Diabetes 2001, 50:1336-1343.
34. Lanng S., Hansen A., Thorsteinsson B., Nerup J., Koch C. Glucose tolerance in patients with cystic fibrosis: five year prospective study. BMJ 1995, 311:655-659.
35. Austin A., Kalhan S.C., Orenstein D., Nixon P., Arslanian S. Roles of insulin resistance and beta-cell dysfunction in the pathogenesis of glucose intolerance in cystic fibrosis. J Clin Endocrinol Metab 1994, 79:80-85.
36. Lanng S., Thorsteinsson B., Roder M.E., Nerup J., Koch C. Insulin sensitivity and insulin clearance in cystic fibrosis patients with normal and diabetic glucose tolerance. Clin Endocrinol (Oxf) 1994, 41:217-223.
37. Moran A., Pyzdrowski K.L., Weinreb J., Kahn B.B., Smith S.A., Adams K.S., et al. Insulin sensitivity in cystic fibrosis. Diabetes 1994, 43:1020-1026.
38. Hardin D.S., LeBlanc A., Para L., Seilheimer D.K. Hepatic insulin resistance and defects in substrate utilization in cystic fibrosis. Diabetes 1999, 48:1082-1087.
39. O'Riordan S.M., Robinson P.D., Donaghue K.C., Moran A. Management of cystic fibrosis-related diabetes. Pediatr Diabetes 2008, 9:338-344.
40. Hanna R., Weiner D. Overweight and obesity in Cystic fibrosis patients. North American Cystic Fibrosis Conference 2012, 419. (Abstract 534), Pediatric Pulmonology, Orlando, FL.
41. European Cystic Fibrosis Society. Patient Registry. Annual Data Report (2008-2009 data). Version 03.2012.
42. Cystic Fibrosis in Australia 2011. 14th annual report from the Australian Cystic Fibrosis Data Registry 2012.
43. Moran A., Hardin D., Rodman D., Allen H.F., Beall R.J., Borowitz D., et al. Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. Diabetes Res Clin Pract 1999, 45:61-73.
44. Finkelstein S.M., Wielinski C.L., Elliott G.R., Warwick W.J., Barbosa J., Wu S.C., et al. Diabetes mellitus associated with cystic fibrosis. J Pediatr 1988, 112:373-377.
45. Marshall B.C., Butler S.M., Stoddard M., Moran A.M., Liou T.G., Morgan W.J. Epidemiology of cystic fibrosis-related diabetes. J Pediatr 2005, 146:681-687.
46. Milla C.E., Warwick W.J., Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med 2000, 162:891-895.
47. Lanng S., Thorsteinsson B., Nerup J., Koch C. Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis. Eur J Pediatr 1992, 151:684-687.
48. Koch C., Rainisio M., Madessani U., Harms H.K., Hodson M.E., Mastella G., et al. Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: data from the European Epidemiologic Registry of Cystic Fibrosis. Pediatr Pulmonol 2001, 32:343-350.
49. Rosenecker J., Hofler R., Steinkamp G., Eichler I., Smaczny C., Ballmann M., et al. Diabetes mellitus in patients with cystic fibrosis: the impact of diabetes mellitus on pulmonary function and clinical outcome. Eur J Med Res 2001, 6:345-350.
50. Moran A., Dunitz J., Nathan B., Saeed A., Holme B., Thomas W. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care 2009, 32:1626-1631.
51. Hameed S., Morton J.R., Jaffe A., Field P.I., Belessis Y., Yoong T., et al. Early glucose abnormalities in cystic fibrosis are preceded by poor weight gain. Diabetes Care 2010, 33:221-226.
52. Moran A., Pekow P., Grover P., Zorn M., Slovis B., Pilewski J., et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care 2009, 32:1783-1788.
53. Hameed S., Morton J.R., Field P.I., Belessis Y., Yoong T., Katz T., et al. Once daily insulin detemir in cystic fibrosis with insulin deficiency. Arch Dis Child 2012, 97:464-467.
54. Bizzarri C., Lucidi V., Ciampalini P., Bella S., Russo B., Cappa M. Clinical effects of early treatment with insulin glargine in patients with cystic fibrosis and impaired glucose tolerance. J Endocrinol Invest 2006, 29:RC1-RC4.
55. Mozzillo E., Franzese A., Valerio G., Sepe A., De Simone I., Mazzarella G., et al. One-year glargine treatment can improve the course of lung disease in children and adolescents with cystic fibrosis and early glucose derangements. Pediatr Diabetes 2009, 10:162-167.
56. Lanng S., Thorsteinsson B., Nerup J., Koch C. Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections. Acta Paediatr 1994, 83:849-853.
57. Nousia-Arvanitakis S., Galli-Tsinopoulou A., Karamouzis M. Insulin improves clinical status of patients with cystic-fibrosis-related diabetes mellitus. Acta Paediatr 2001, 90:515-519.
58. Dobson L., Hattersley A.T., Tiley S., Elworthy S., Oades P.J., Sheldon C.D. Clinical improvement in cystic fibrosis with early insulin treatment. Arch Dis Child 2002, 87:430-431.
59. Schwarzenberg S.J., Thomas W., Olsen T.W., Grover T., Walk D., Milla C., et al. Microvascular complications in cystic fibrosis-related diabetes. Diabetes Care 2007, 30:1056-1061.
60. Yahiaoui Y., Jablonski M., Hubert D., Mosnier-Pudar H., Noel L.H., Stern M., et al. Renal involvement in cystic fibrosis: diseases spectrum and clinical relevance. Clin J Am Soc Nephrol 2009, 4:921-928.
61. Coderre L., Fadainia C., Belson L., Belisle V., Ziai S., Maillhot G., et al. LDL-cholesterol and insulin are independently associated with body mass index in adult cystic fibrosis patients. J Cyst Fibros 2012, 11:393-397.
62. Kastner-Cole D., Palmer C.N., Ogston S.A., Mehta A., Mukhopadhyay S. Overweight and obesity in deltaF508 homozygous cystic fibrosis. J Pediatr 2005, 147:402-404.
63. Andersen H.U., Lanng S., Pressler T., Laugesen C.S., Mathiesen E.R. Cystic fibrosis-related diabetes: the presence of microvascular diabetes complications. Diabetes Care 2006, 29:2660-2663.
64. Bradbury R.A., Shirkhedkar D., Glanville A.R., Campbell L.V. Prior diabetes mellitus is associated with increased morbidity in cystic fibrosis patients undergoing bilateral lung transplantation: an 'orphan' area? A retrospective case-control study. Intern Med J 2009, 39:384-388.
65. van Meerkerk G., van de Graaf E.A., Kwakkel-van Erp J.M., van Kessel D.A., Lammers J.W., Biesma D.H., et al. Diabetes before and after lung transplantation in patients with cystic fibrosis and other lung diseases. Diabet Med 2012.
66. Moran A. Cystic fibrosis-related diabetes: an approach to diagnosis and management. Pediatr Diabetes 2000, 1:41-48.
67. Moran A., Brunzell C., Cohen R.C., Katz M., Marshall B.C., Onady G., et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 2010, 33:2697-2708.
68. O'Riordan S.M., Robinson P.D., Donaghue K.C., Moran A. Management of cystic fibrosis-related diabetes in children and adolescents. Pediatr Diabetes 2009, 10(Suppl. 12):43-50.
69. Lombardo F., De Luca F., Rosano M., Sferlazzas C., Lucanto C., Arrigo T., et al. Natural history of glucose tolerance, beta-cell function and peripheral insulin sensitivity in cystic fibrosis patients with fasting euglycemia. Eur J Endocrinol 2003, 149:53-59.
70. Succurro E., Marini M.A., Arturi F., Grembiale A., Lugara M., Andreozzi F., et al. Elevated one-hour post-load plasma glucose levels identifies subjects with normal glucose tolerance but early carotid atherosclerosis. Atherosclerosis 2009, 207:245-249.
71. Frohnert B.I., Ode K.L., Moran A., Nathan B.M., Laguna T., Holme B., et al. Impaired fasting glucose in cystic fibrosis. Diabetes Care 2010, 33:2660-2664.
72. Godbout A., Hammana I., Potvin S., Mainville D., Rakel A., Berthiaume Y., et al. No relationship between mean plasma glucose and glycated haemoglobin in patients with cystic fibrosis-related diabetes. Diabetes Metab 2008, 34:568-573.
73. Dobson L., Sheldon C.D., Hattersley A.T. Conventional measures underestimate glycaemia in cystic fibrosis patients. Diabet Med 2004, 21:691-696.
74. O'Riordan S.M., Hindmarsh P., Hill N.R., Matthews D.R., George S., Greally P., et al. Validation of continuous glucose monitoring in children and adolescents with cystic fibrosis: a prospective cohort study. Diabetes Care 2009, 32:1020-1022.
75. Dyce P., Daniels J., Dunne J., Govin B., Malone V., Nazareth D., et al. Continuous glucose monitoring for cystic fibrosis: sweet success or bitter disappointment. North American Cystic Fibrosis Conference 2012, 420. (Abstract 436), Pediatric Pulmonology, Orlando, FL.
76. Rana M., Munns C.F., Selvadurai H.C., Simonds S., Cooper P.J., Woodhead H.J., et al. Increased detection of cystic-fibrosis-related diabetes in Australia. Arch Dis Child 2011, 96:823-826.
77. Mozzillo E., Raia V., Fattorusso V., Falco M., Sepe A., De Gregorio F., et al. Glucose derangements in very young children with cystic fibrosis and pancreatic insufficiency. Diabetes Care 2012, 35:e78.
78. Ode K.L., Frohnert B., Laguna T., Phillips J., Holme B., Regelmann W., et al. Oral glucose tolerance testing in children with cystic fibrosis. Pediatr Diabetes 2010, 11:487-492.
79. Gunnarsson R., Lundgren G., Magnusson G., Ost L., Groth C.G. Steroid diabetes-a sign of overtreatment with steroids in the renal graft recipient?. Scand J Urol Nephrol Suppl 1980, 54:135-138.
80. Hathout E., Alonso E., Anand R., Martz K., Imseis E., Johnston J., et al. Post-transplant diabetes mellitus in pediatric liver transplantation. Pediatr Transplant 2009, 13:599-605.
81. Heisel O., Heisel R., Balshaw R., Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004, 4:583-595.
82. Ye X., Kuo H.T., Sampaio M.S., Jiang Y., Bunnapradist S. Risk factors for development of new-onset diabetes mellitus after transplant in adult lung transplant recipients. Clin Transplant 2011, 25:885-891.
83. Grover P., Thomas W., Moran A. Glargine versus NPH insulin in cystic fibrosis related diabetes. J Cyst Fibros 2008, 7:134-136.
84. Mudaliar S.R., Lindberg F.A., Joyce M., Beerdsen P., Strange P., Lin A., et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 1999, 22:1501-1506.
85. Sulli N., Shashaj B. Continuous subcutaneous insulin infusion in children and adolescents with diabetes mellitus: decreased HbA1c with low risk of hypoglycemia. J Pediatr Endocrinol Metab 2003, 16:393-399.
86. Sulli N., Bertasi S., Zullo S., Shashaj B. Use of continuous subcutaneous insulin infusion in patients with cystic fibrosis related diabetes: three case reports. J Cyst Fibros 2007, 6:237-240.
87. Onady G.M., Stolfi A. Insulin and oral agents for managing cystic fibrosis-related diabetes. Cochrane Database Syst Rev 2005, CD004730.
88. Standardization of spirometry--1987 update. Statement of the American Thoracic Society. Am Rev Respir Dis 1987, 136:1285-1298.
89. Battezzati A., Battezzati P.M., Costantini D., Seia M., Zazzeron L., Russo M.C., et al. Spontaneous hypoglycemia in patients with cystic fibrosis. Eur J Endocrinol 2007, 156:369-376.
90. Radike K., Molz K., Holl R.W., Poeter B., Hebestreit H., Ballmann M. Prognostic relevance of hypoglycemia following an oral glucose challenge for cystic fibrosis-related diabetes. Diabetes Care 2011, 34:e43.
91. Stanley C.A., Baker L. The causes of neonatal hypoglycemia. N Engl J Med 1999, 340:1200-1201.
92. Service F.J. Hypoglycemic disorders. N Engl J Med 1995, 332:1144-1152.
93. Lev-Ran A. Nadirs of oral glucose tolerance tests are independent of age and sex. Diabetes Care 1983, 6:405-408.
94. Palladino A.A., Sayed S., Levitt Katz L.E., Gallagher P.R., De Leon D.D. Increased glucagon-like peptide-1 secretion and postprandial hypoglycemia in children after Nissen fundoplication. J Clin Endocrinol Metab 2009, 94:39-44.
95. Christensson C., Thoren A., Lindberg B. Safety of inhaled budesonide: clinical manifestations of systemic corticosteroid-related adverse effects. Drug Saf 2008, 31:965-988.
96. Kennedy M.J., Carpenter J.M., Lozano R.A., Castile R.G. Impaired recovery of hypothalamic-pituitary-adrenal axis function and hypoglycemic seizures after high-dose inhaled corticosteroid therapy in a toddler. Ann Allergy Asthma Immunol 2002, 88:523-526.
97. Todd G.R., Acerini C.L., Buck J.J., Murphy N.P., Ross-Russell R., Warner J.T., et al. Acute adrenal crisis in asthmatics treated with high-dose fluticasone propionate. Eur Respir J 2002, 19:1207-1209.
98. Zollner E.W., Lombard C., Galal U., Hough S., Irusen E., Weinberg E. Hypothalamic-pituitary-adrenal axis suppression in asthmatic children on inhaled and nasal corticosteroids-more common than expected?. J Pediatr Endocrinol Metab 2011, 24:529-534.
99. Hoover W.C., Britton L.J., Gardner J., Jackson T., Gutierrez H. Rapid onset of iatrogenic adrenal insufficiency in a patient with cystic fibrosis-related liver disease treated with inhaled corticosteroids and a moderate CYP3A4 inhibitor. Ann Pharmacother 2011, 45:e38.
100. Collins S., Reynolds F. How do adults with cystic fibrosis cope following a diagnosis of diabetes?. J Adv Nurs 2008, 64:478-487.
101. Phillips L.S., Ziemer D.C., Kolm P., Weintraub W.S., Vaccarino V., Rhee M.K., et al. Glucose challenge test screening for prediabetes and undiagnosed diabetes. Diabetologia 2009, 52:1798-1807.
102. Minicucci L., Haupt M., Casciaro R., De Alessandri A., Bagnasco F., Lucidi V., et al. Slow-release insulin in cystic fibrosis patients with glucose intolerance: a randomized clinical trial. Pediatr Diabetes 2012, 13:197-202.
103. Vilsboll T., Brock B., Perrild H., Levin K., Lervang H.H., Kolendorf K., et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med 2008, 25:152-156.
104. Takeda Y., Fujita Y., Honjo J., Yanagimachi T., Sakagami H., Takiyama Y., et al. Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice. Diabetologia 2012, 55:404-412.
105. Pospisilik J.A., Ehses J.A., Doty T., McIntosh C.H., Demuth H.U., Pederson R.A. Dipeptidyl peptidase IV inhibition in animal models of diabetes. Adv Exp Med Biol 2003, 524:281-291.
106. Mu J., Woods J., Zhou Y.P., Roy R.S., Li Z., Zycband E., et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006, 55:1695-1704.
107. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002, 346:1685-1691.
108. Brodsky J., Dougherty S., Makani R., Rubenstein R.C., Kelly A. Elevation of 1-hour plasma glucose during oral glucose tolerance testing is associated with worse pulmonary function in cystic fibrosis. Diabetes Care 2011, 34:292-295.
109. Kanat M., Mari A., Norton L., Winnier D., DeFronzo R.A., Jenkinson C., et al. Distinct beta-cell defects in impaired fasting glucose and impaired glucose tolerance. Diabetes 2012, 61:447-453.
110. Abdul-Ghani M.A., Abdul-Ghani T., Stern M.P., Karavic J., Tuomi T., Bo I., et al. Two-step approach for the prediction of future type 2 diabetes risk. Diabetes Care 2011, 34:2108-2112.
111. Edlund A., Huhn M., Flodstrom-Tullberg M., Eliasson L. Active CFTR channels are important for insulin and glucagon secretion. Acta Physiol 2010, (Suppl. 677):O13.
112. Boom A., Lybaert P., Pollet J.F., Jacobs P., Jijakli H., Golstein P.E., et al. Expression and localization of cystic fibrosis transmembrane conductance regulator in the rat endocrine pancreas. Endocrine 2007, 32:197-205.
113. Olivier A.K., Yi Y., Sun X., Sui H., Liang B., Hu S., et al. Abnormal endocrine pancreas function at birth in cystic fibrosis ferrets. J Clin Invest 2012, 122:3755-3768.